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.2011.12.0Abstract Aim of the present study was to improve the solubility and dissolution rate of poorly
water soluble, BCS class-II drug Ketoprofen (KETO) by solid-dispersion approach. Solid disper-
sions were prepared by using polyvinylpyrrolidone K30 (PVPK30) and D-mannitol in different drugs
to carrier ratios. Dispersions with PVP K30 were prepared by kneading and solvent evaporation
techniques, whereas solid dispersions containing D-mannitol were prepared by kneading and melting
techniques. These formulations were characterized in the liquid state by phase-solubility studies and
in the solid state by Differential Scanning Calorimetry (DSC), Fourier Transform Infrared (FTIR)
spectroscopy, X-ray diffraction (XRD) and Scanning ElectronMicroscopy (SEM). The aqueous sol-
ubility of KETO was favored by the presence of both carriers. The negative values of Gibbs free
energy illustrate the spontaneous transfer from pure water to the aqueous polymer environment.
Solid state characterization indicated KETO was present as ﬁne particles in D-mannitol solid disper-
sions and entrapped in carrier matrix of PVP K30 solid dispersions. In contrast to the very slow dis-
solution rate of pure KETO, dispersions of drug in carriers considerably improved the dissolution
rate. This can be attributed to increased wettability and dispersibility, as well as decreased crystallin-
ity and increase in amorphous fraction of drug. Solid dispersions prepared with PVPK30 showed the
highest improvement in dissolution rate of KETO. Even physical mixtures of KETO prepared with
both carriers also showed better dissolution proﬁles than those of pure KETO.
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(P.S. Yadav).
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071. Introduction
Poorly water-soluble drugs are associated with slow drug
absorption leading eventually to inadequate and variable bio-
availability (Amidon et al., 1995; Leuner and Dressman,
2000). Nearly 40% of the new chemical entities currently being
discovered are poorly water-soluble drugs (Lipinski, 2002; Huier B.V. All rights reserved.
78 P.S. Yadav et al.et al., 2004). Based upon their permeability characteristics, the
Biopharmaceutical Classiﬁcation System (BCS) categorizes
such drugs into two major classes, viz. Class II and IV (Amidon
et al., 1995; http://www.fda.gov/downloads/Drugs/Guidance-
ComplianceRegulatoryInformation/Guidances/ucm070246.
pdf). The BCS class II drugs encompass poorly water-soluble
entities with high permeability. Attempts to enhance drug solu-
bility of these therapeutic agents correlate well with enhance-
ment in their bioavailability (Amidon et al., 1995; Leuner and
Dressman, 2000; http://www.fda.gov/downloads/Drugs/Guid-
anceComplianceRegulatoryInformation/Guidances/ucm070246.
pdf). Most formulation strategies for such drugs are targeted at
enhancing their dissolution rate and/or solubility by achieving
their ﬁne dispersion at absorption level (Leuner and Dressman,
2000; Wyatt, 1999; Craig, 1993). This can be attained by formu-
lating supersaturated systems (i.e., solid dispersion) of the drug
employing diverse types of carriers, ranging widely from water-
soluble to amphiphilic to lipid-soluble ones (Leuner and Dress-
man, 2000; Habib, 2001; Serajuddin, 1999; Charman, 2000). So-
lid dispersion is a group of solid product consisting, generally, a
hydrophobic drug and hydrophilicmatrix. This approach is use-
ful for the improvement of solubility of poorly soluble drugs.
Ketoprofen is Non-Steroidal Anti-Inﬂammatory Drug
(NSAID) of propionic acid class having analgesic and anti
pyretic effects. In BCS, it is categorized in Class II (http://
www.tsrlinc.com/resources/services/). Solid-dispersion strat-
egy has been experimented for KETO, and various carriers
have been tested (Margarit et al., 1994; Roger and Ander-
son, 1982; Sheen et al., 1995; Takayama et al., 1982). Here
authors have formulated solid dispersions of KETO with
some more carriers (i.e., PVP K30 and D-mannitol) by vari-
ous methods with the objective to improve the solubility of
the same.2. Materials and methods
2.1. Materials
For preparation of solid dispersions the following materials
were used: Ketoprofen (Gift sample from Alembic Pvt. Ltd.,
India); polyvinylpyrrolidone K30 (Gift sample from Sun Phar-
maceutical Industries, India): D-(-) Mannitol Extra pure (Loba
Chemie Indoaustranal Co., India). Analytical grade of solvents
were used.2.2. Phase solubility studies
Phase-solubility studies were carried out by adding excess of
drug (60 mg) in 25 ml of aqueous solution of different (5%,
10%, 15% and 20%) PVP or D-mannitol concentrations.
The suspensions were continuously stirred on an electromag-
netic stirrer with a hot plate (Remi, India) at 37 C and
300 rpm for 48 h (this duration was previously tested to be suf-
ﬁcient to reach equilibrium). The suspensions were ﬁltered
through a 0.22 lm nylon membrane ﬁlter. The ﬁltrates were
suitably diluted and analyzed, spectrophotometrically (UV-
1700, UV/Vis spectrophotometer, Shimadzu, Japan), for the
dissolved drug at 259 nm. All assays were performed in
triplicate.The Gibbs free energy of transfer (DG0tr) of KETO from
pure water to the aqueous solution of carrier was calculated
as follows:
DG0tr ¼ 2:303RT logS0=SS
where S0/SS is the ratio of molar solubility of KETO in aque-
ous solutions of carrier to that of the same medium without
carrier.
1:1 complex apparent stability constant (Ka) was deter-
mined as follows:
Ka ¼ Slope
Interceptð1 SlopeÞ
where slope and intercept were obtained from the graph of
%w/v of ketoprofen vs. aqueous concentration of carrier
(PVP K30 and D-mannitol) in %w/v.
2.3. Preparation of solid dispersion
Solid dispersions were prepared by three different methods and
were compared with the drug carrier physical mixture and pure
KETO.
2.3.1. Melting method
Three solid-dispersion preparations containing different
weight ratios of KETO in D-mannitol (1:1, 1:3, 1:5, and de-
noted as MMDM 1:1, 1:3, 1:5, respectively) were prepared
by the melting method. KETO was added to the melted D-
mannitol at 168 C, and the resulting homogeneous prepara-
tion was rapidly cooled in a freezing mixture of ice and sodium
chloride and stored in a desiccator for 24 h. Subsequently, the
dispersion was ground in a mortar and sieved through 60#
sieve. The resulted product was stored in a desiccator until fur-
ther evaluation.
2.3.2. Solvent evaporation method
Solid dispersions of KETO in PVP K30 containing different
weight ratios (1:1, 1:3, 1:5 and denoted as SMPVP 1:1, 1:3,
1:5, respectively) were prepared by the solvent evaporation
method as follows. To a solution of weighed quantity of
KETO in a minimum amount of ethanol, the appropriate
amount of PVP K30 was added. The resulting mixture was
stirred for 1 h and evaporated at a temperature of 45–50 C
on water bath until nearly dry and then stored in a desiccator
over anhydrous CaCl2, to constant weight. The evaporated
product was ground in a mortar and passed through a sieve
60# and stored in a desiccator until further evaluation.
2.3.3. Kneading method
Solid Dispersions of KETO in PVP K30 in different weight ra-
tios (1:1, 1:3, 1:5 and denoted as KMPVP 1:1, 1:3, 1:5, respec-
tively) and D-mannitol in different weight ratios (1:1, 1:3, 1:5
and denoted as KMDM 1:1, 1:3, 1:5, respectively) were pre-
pared by the kneading method as follows. A mixture of PVP
K30 and KETO was wetted with water and kneaded thor-
oughly for 30 min in a glass mortar. The paste formed was
dried for 24 h. Dried powder was passed through 60# sieve
and stored in a desiccator until further evaluation.
2.3.4. Physical mixtures
Physical mixtures having the same weight ratios were prepared
by thoroughly mixing appropriate amounts of KETO and PVP
Figure 1 Solubility of KETO (g/100 ml) in aqueous solutions of
PVP K30 and D-mannitol in water at 37 C. (Each point represents
mean of three determinations.)
Figure 2 Comparative study of the FTIR spectra of (a) pure
drug KETO; (b) PVP K30; (c) PMPVP 1:5; (d) KMPVP 1:5 and
(e) SMPVP 1:5.
Table 1 Gibbs free energy values and apparent stability
constants (Ka) of KETO-PVP K30 and KETO–D-mannitol
interactions.
Concentration (% w/v) DG0tr (kJ/mol)
PVP K30 D-mannitol
5 22.18 19.77
10 24.52 21.51
15 25.33 21.81
20 25.84 23.13
Intercept 1.51 · 104 4.91 · 105
Slope 1.79 · 102 5.66 · 3
Ka 120.87 115.85
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PMPVP 1:1, 1:3, 1:5, respectively) and D-mannitol in different
weight ratios (1:1, 1:3, 1:5 and denoted as PMDM 1:1, 1:3, 1:5,
respectively) in a mortar until a homogeneous mixture was ob-
tained. The resulting mixtures were sieved through a 60# sieve.
The resulted product was stored in a desiccator until further
evaluation.
2.4. Characterization of solid dispersion
2.4.1. Fourier Transform Infrared Spectroscopy (FTIR)
FTIR spectra of powder samples were obtained by using a
spectrophotometer (Shimadzu, 8400) by potassium bromide
(KBr) pellet method (2 mg of sample in 200 mg of KBr). The
scanning range was 650–3800 cm1 and the resolution was
2 cm1.
2.4.2. X-ray diffraction (XRD)
Powder XRD patterns were traced employing X-ray diffrac-
tometer (Philips PW 1830, The Netherlands) for the samples,
using Ni ﬁltered CuKa radiation of wavelength 1.5404 A˚, a
voltage of 35 kV, a current of 30 mA and receiving slit of
0.1 mm. The samples were analyzed over 2h range of 4–40
with a scan step size of 0.05 and a scan step time of 1 s and
a scanning rate of 4/min.
2.4.3. Differential scanning calorimetry (DSC)
DSC scans of the powdered samples were recorded by using
Jade DSC Perkin Elmer, USA. All samples were weighed (8–
10 mg) and heated at a scanning rate of 10 C/min under drynitrogen ﬂow (20 ml/min) between 50 and 300 C. Aluminum
pans and lids were used for all samples. Pure water and indium
were used to calibrate the DSC temperature scale and enthal-
pic response.
2.4.4. Scanning electron microscopy (SEM)
The SEM analysis was carried out using a scanning electron
microscope (Hitachi S-3600 N, Japan). Prior to examination,
samples were mounted on an aluminum stub using a double
sided adhesive tape and then making it electrically conductive
by coating with a thin layer of gold (approximately 20 nm) in
vacuum. The scanning electron microscope was operated at an
acceleration voltage of 15 kV.
2.5. In vitro dissolution study
In vitro dissolution studies were carried out for pure drug and
all products in USP type II dissolution test apparatus (Camp-
bell Electronics, India) at 50 RPM in 900 ml of 0.1MHCl.
Fifty milligrams of pure drug and an equivalent amount of so-
lid dispersion were used for the dissolution studies. One milli-
liter of the aliquot was withdrawn at predetermined intervals
and ﬁltered using 0.22 lm nylon membrane (Pall Life Sciences,
India). The required dilutions were made with 0.1 M HCl and
Figure 3 FTIR spectra of (a) pure drug KETO; (b) D-mannitol;
(c) PMDM 1:5; (d) KMDM 1:5 and (e) MMDM 1:5.
80 P.S. Yadav et al.the solution was analyzed for the drug content UV spectropho-
tometrically at 259 nm against 0.1 M HCl. An equal volume of
the dissolution medium was replaced in the vessel after each
withdrawal to maintain the sink condition. Three determina-
tions were carried out for each formulation. From this, cumu-
lative % of dug dissolved was calculated and plotted against
function of time to study the pattern of drug release. Each test
was performed in triplicate (n= 3), and calculated mean val-
ues of cumulative drug release were used while plotting the re-
lease curves. DP30 min (drug dissolved within 30 min) values for
release of KETO from different samples were calculated.Figure 4 Powder X-ray diffractograms of (a) pure drug KETO;
(b) PVP K30; (c) PMPVP 1:5; (d) KMPVP 1:5 and (e) SMPVP 1:5.2.6. Statistical analysis
For comparison between dissolution proﬁles of different sam-
ples, an independent mathematical approach model for calcu-
lating a similarity factor f2 proposed by Moore and Flanner
(1996) was used. The similarity factor f2 is a measure of simi-
larity in the percentage dissolution between two dissolution
curves and is deﬁned by the following equation:
f2 ¼ 50 log 1þ 1
n
 Xn
t¼1
wtðRt  TtÞ2
( )0:5
 100
2
4
3
5
where n is the number of withdrawal points, Rt is the percent-
age dissolved of reference at time point t, and Tt is the percent-
age dissolved of test at time point t. A value of 100% for the
similarity factor (f2) suggests that the test and reference proﬁles
are identical. Values between 50 and 100 indicate that the dis-
solution proﬁles are similar, whereas smaller values imply an
increase in dissimilarity between release proﬁles. CDER/
FDA (http://www.fda.gov/downloads/Drugs/GuidanceCom-
plianceRegulatoryInformation/Guidances/ucm070237.pdf)
suggests this analysis for an immediate release of solid oral
dosage forms.
3. Results and discussion
3.1. Phase solubility studies
Fig. 1 represents solubility of KETO in the presence of PVP
K30 and D-mannitol. The Gibbs free energy of transfer
(DG0tr) and apparent stability constants (Ka) derived from
Fig. 1 are shown in Table 1. The plots of drug solubility
against the polymer concentration (Fig. 1) indicate a linearFigure 5 Powder XRD spectra of (a) pure drug KETO; (b) D-
mannitol; (c) PMDM 1:5; (d) KMDM 1:5 and (e) MMDM 1:5.
Figure 6 DSC thermograms of (a) pure drug KETO; (b) PVP K30; (c) PMPVP 1:5; (d) KMPVP 1:5; (e) SMPVP 1:5; (f) D-mannitol; (g)
PMDM 1:5; (h) KMDM 1:5 and (i) MMDM 1:5.
Figure 7 SEM photomicrographs of (a) pure drug KETO (400·); (b) PVP K30 (400·); (c) PMPVP 1:5 (120·); (d) KMPVP 1:5 (200·); (e)
SMPVP 1:5 (120·); (f) D-mannitol (400·); (g) PMDM 1:5 (400·); (h) KMDM 1:5 (400·) and (i) MMDM 1:5 (400·).
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Figure 8 In vitro dissolution proﬁles of pure KETO and its
physical mixtures and solid dispersions with PVP K30 (n= 3).
Figure 9 In vitro dissolution proﬁles of pure KETO and its
physical mixtures and solid dispersions with D-mannitol (n= 3).
Table 2 % Drug dissolved within 30 min (DP30min) (n= 3).
Sample DP30min (Mean ± SD)
Pure KETO 12.11 ± 0.231
PMPVP 1:1 53.6 ± 0.467
PMPVP 1:3 56.0 ± 0.547
PMPVP 1:5 62.6 ± 0.649
PMDM 1:1 36.64 ± 0.548
PMDM 1:3 51.62 ± 0.657
PMDM 1:5 63.76 ± 0.986
KMPVP 1:1 18.05 ± 0.675
KMPVP 1:3 22.70 ± 0.745
KMPVP 1:5 59.63 ± 0.863
KMDM 1:1 63.80 ± 0.688
KMDM 1:3 65.82 ± 0.876
KMDM 1:5 72.28 ± 1.238
MMDM 1:1 43.4 ± 0.654
MMDM 1:3 55.23 ± 0.761
MMDM 1:5 66.34 ± 0.922
SMPVP 1:1 52.14 ± 0.542
SMPVP 1:3 67.89 ± 0.764
SMPVP 1:5 75.89 ± 0.871
82 P.S. Yadav et al.relationship (AL type of curve) in the investigated polymer
concentration range.
Table 1 shows that all values of DG0tr were negative at all
levels of carriers, demonstrating spontaneity of drug solubili-
zation process. The values show a declining trend with increase
in the carrier concentration too construing that the process is
more favorable at higher carrier levels. Table 1 also indicates
that KETO-PVP K30 interaction has a higher Ka value. The
higher Ka value indicates that the binding afﬁnity between
KETO-PVP K30 is more than that of KETO-D-mannitol.
The results show that in both cases, the solubility of KETO in-
creased with increasing carrier concentration.
3.2. Fourier Transform Infrared Spectroscopy (FTIR) analysis
FTIR spectra of solid dispersions of KETO with PVP K30 and
D-mannitol are shown in Figs. 2 and 3, respectively. The spec-
tra of pure KETO presented characteristic peaks at 1693 cm1
(C‚O stretching of acid), 1655 cm1 (C‚O stretching of ke-
tone), 1598, 1580, 1455 cm1 (C‚C stretching of aromaticring), 1440 cm1 (C–H deformation of CH3 asymmetrical),
1370 cm1 (C–H deformation of CH3 symmetrical), respec-
tively. The characteristic peaks of KETO at 1693 cm1
(C‚O stretching of acid), 1655 cm1 (C‚O stretching of aro-
matic ring), 1440 cm1 (C–H deformation of CH3 asymmetri-
cal) are also present in spectra of PMPVP 1:5. In the case of
KMPVP 1:5 and SMPVP 1:5, a peak at 1455 cm1 (C‚C
stretching of aromatic ring) can be assigned for the presence
of KETO.
By comparison of spectra of PMDM 1:5, KMDM 1:5,
MMDM 1:5, no difference was shown in the position of the
absorption bands. Therefore, the spectra can be simply re-
garded as the superposition of those of KETO and D-mannitol.
Therefore, it could be concluded that KETO does not interact
with mannitol. Most of the other peaks due to KETO were ab-
sent in the spectra of KMPVP 1:5 and SMPVP 1:5 indicating
trapping of KETO inside the PVP matrix.
3.3. X-ray diffraction (XRD) analysis
Powder XRD of pure KETO, its physical mixtures and solid
dispersions with PVP K30 and D-mannitol are shown in Figs. 4
and 5, respectively. The presence of numerous distinct peaks in
the X-ray diffraction spectrum indicates that KETO is present
as a crystalline material with characteristic diffraction peaks
appearing at a diffraction angle of 2h at 6.33, 13.16, 14.42,
16.22, 17.30, 18.42, 19.15, 20.04, 22.91, 23.95, 27.23, 27.73,
29.49, etc. Spectroscopy of PVP K30 (Fig. 4b) was character-
ized by the complete absence of any diffraction peak. PMPVP
1:5, KMPVP 1:5, SMPVP 1:5 (Fig. 4c–e) showed the same dif-
fraction pattern with most of the diffraction peaks correspond-
ing to the drug indicating that KETO was in an amorphous
state.
D-Mannitol exhibited a distinct pattern with diffraction
peaks (Fig. 5b) at 2h at 14.60, 16.78, 18.75, 20.44, 21.06,
23.39, 28.28, 29.48, 31.75, 33.57, 38.72, etc. PMDM 1:5,
KMDM 1:5 and MMDM 1:5 showed the presence of charac-
teristic diffraction peaks of both drug and carrier, indicating
that KETO was present as crystalline material.
Moreover, no peaks other than those that could be assigned
to pure KETO and PVP K30 or D-mannitol were detected in
Figs. 4 and 5, respectively.
Table 3 Similarity factor (f2) for release proﬁles of KETO from solid dispersions and physical mixtures with PVP K30.
Sample KETO SMPVP 1:5 SMPVP 1:3 SMPVP 1:1 KMPVP 1:5 KMPVP 1:3 KMPVP 1:1
KETO – 11.72 15.27 20.98 19.10 48.23 66.65
PMPVP 1:5 18.30 37.90 – – 74.42 – –
PMPVP 1:3 19.53 – 39.95 – – 25.34 –
PMPVP 1:1 22.87 – – 47.51 – – 25.40
KMPVP 1:5 – 35.02 – – – – –
KMPVP 1:3 – – 19.07 – – – –
KMPVP 1:1 – – – 23.60 – – –
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DSC curves obtained for pure KETO, PVP K30, D-mannitol,
their physical mixtures and solid dispersions prepared with
PVP K30 and D-mannitol, are shown in Fig. 6. Pure powdered
KETO thermogram showed a melting endotherm at 92.75 C
with enthalpy of fusion (DH) 113.08 J/g. Scanning of PVP
K30, a broad endotherm ranging from 80 to 120 C was ob-
served, because of the presence of residual moisture in PVP
K30. The DSC thermogram of PMPVP 1:5 showed a broad
peak at 113.53 C indicating drug amorphization. KMPVP
1:5 and SMPVP 1:5 (Fig. 6d and e) showed broad endotherm
due to the presence of water ranging from 80 to 120 C in PVP
K30 and a complete absence of drug peak at 93 C. This indi-
cates that KETO is present as amorphous or solid solution in-
side the PVP K30 matrix.
DSC scan of D-mannitol showed single sharp endotherm at
166.29 C due to melting of D-mannitol, whereas during DSC
thermograms of PMDM 1:5, KMDM 1:5, MMDM 1:5
showed the melting peak of the drug at 93 C and sharp endo-
thermic peak at 166 C due to the melting of D-mannitol indi-
cating that there is no physical or chemical interaction between
KETO and D-mannitol.3.5. Scanning Electron Microscopy (SEM) analysis
SEM photomicrographs obtained for pure KETO, PVP K30,
D-mannitol, their physical mixtures and solid dispersions pre-
pared with PVP K30 and D-mannitol, are shown in Fig. 7 in
selected magniﬁcations. From the photomicrograph of pure
drug KETO, it is clear that the drug was present as irregular
shaped crystals. In PMPVP 1:5 and PMDM 1:5, drug particles
were adsorbed on the carrier particles. While in the photomi-
crograph of KMDM 1:5, it can be seen that drug particles
are adsorbed on carrier with decreased particle size. This par-
ticle size reduction is more efﬁciently seen with MMDM 1:5.
SEM photomicrographs of KMPVP 1:5 and SMPVP 1:5 showTable 4 Similarity factor (f2) for release proﬁles of KETO from so
Sample KETO MMDM 1:5 MMDM 1:3 M
KETO – 15.97 22.06 2
PMDM 1:5 18.29 52.79 –
PMDM 1:3 22.72 – 53.68
PMDM 1:1 27.73 – – 5
KMDM 1:5 – 62.39 –
KMDM 1:3 – – 47.13
KMDM 1:1 – – – 3that the drug particles are entrapped within the carrier matrix,
conﬁrming FTIR, XRD and DSC data analyses.3.6. In vitro dissolution studies
Dissolution of pure KETO and all other prepared systems (so-
lid dispersions and physical mixtures) were carried out in
0.1MHCl. DP30min (percent drug dissolved within 30 min) val-
ues were reported in Table 2. From these data it is evident that
the onset of dissolution of pure KETO is very low (DP30min va-
lue 12.11%).
Dissolution proﬁles of pure KETO, its physical mixtures
and solid dispersions with PVP K30 and D-mannitol over a
period of 1 h are shown in Figs. 8 and 9, respectively. It can
be clearly observed that the dissolution rate of pure KETO
is low because 20.89% of drug dissolved in 1 h. Solid disper-
sions of KETO with PVP K30 and D-mannitol signiﬁcantly en-
hanced the dissolution rate of KETO (58–87% with both
carriers) within 1 h as compared to physical mixtures as well
as pure KETO. Highest improvement was observed in solid
dispersions prepared by the solvent evaporation method with
PVP K30 (SMPVP 1:5) while in the case of solid dispersions
prepared with D-mannitol, the improvement in dissolution rate
was higher for MMDM 1:5.
3.7. Statistical analysis
Comparisons between the release proﬁles of KETO from dif-
ferent samples were made by similarity factor f2. Calculated
f2 values for PVP K30 and D-mannitol formulations are pre-
sented in Tables 3 and 4, respectively.
From Table 3 it is evident that the release proﬁle of KETO
from all the samples (i.e., solid dispersions and physical mix-
tures with PVP K30) and from pure KETO were dissimilar be-
cause f2 values for all comparisons were less than 50 except
KMPVP 1:1. Release proﬁles of KETO from KMPVP and
PMPVP at 1:5 ratios were also similar. Table 4 shows thatlid dispersions and physical mixtures with D-mannitol.
MDM 1:1 KMDM 1:5 KMDM 1:3 KMDM 1:1
7.93 15.14 16.49 18.06
– 55.18 – –
– – 42.49 –
9.63 – – 35.82
– – – –
– – – –
9.79 – – –
84 P.S. Yadav et al.the release proﬁle of KETO from all the samples (i.e., solid dis-
persions and physical mixtures with D-mannitol) and from
pure KETO were dissimilar because f2 values for all the com-
parisons were less than 50. But release proﬁles of KETO from
MMDM and PMDM at different ratios, KMDM and PMDM
at 1:5 ratios and MMDM and KMDM at 1:5 ratios were
similar.
4. Conclusion
From this study, the increase in dissolution rates of KETO,
when dispersed in PVP K30 or D-mannitol, can be observed.
Solubility studies showed a solubilizing effect of both carriers
on KETO. The negative values of Gibbs free energy indicated
spontaneity of transfer. XRD, DSC and SEM studies of
KETO-PVP K30 solid dispersions indicated that the drug
was entrapped within the carrier (PVP K30) matrix while in
the case of KETO–D-mannitol mixtures the drug was adsorbed
as ﬁne particles on the surface of carrier (D-mannitol). In these
systems drug carrier interaction was shown with the use of
FTIR. The dissolution rates of physical mixtures were higher
than those of pure drug, which was possibly caused by in-
creased drug wettability. Solid dispersions demonstrated high-
er dissolution rates than physical mixtures. The increased
dissolution rates in systems containing D-mannitol were prob-
ably the result of decreased particle size, increased wettability
and dispersibility of KETO, and in the case of PVP K30 sys-
tems that was due to surface tension lowering effect of PVP
K30 to the medium, resulting in wetting of hydrophobic and
BCS class-II drug (KETO) and thus increase in dissolution
rates. SMPVP 1:5 is the best combination for solid dispersions
in this study.
References
Amidon, G.L., Lennernas, H., Shah, V.P., Crison, J.R., 1995. A
theoretical basis for a biopharmaceutic drug classiﬁcation: the
correlation of in vitro drug product dissolution and in vivo
bioavailability. Pharm. Res. 12, 413–420.
Charman, W.N., 2000. Lipids, lipophilic drugs, and oral drug delivery:
some emerging concepts. J. Pharm. Sci. 89, 967–978.Craig, D.Q.M., 1993. The use of self-emulsifying systems as a means of
improving drug delivery. In: Bulletin Technique Gattefosse, pp. 21–
31.
Habib, M.J., 2001. Pharmaceutical Solid Dispersion Technology, ﬁrst
ed. Technomic Publishing, Lancaster.
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulato-
ryInformation/Guidances/ucm070246.pdf (Accessed on January
21, 2011).
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulato-
ryInformation/Guidances/ucm070237.pdf (Accessed on January
21, 2011).
http://www.tsrlinc.com/resources/services/ (Accessed on January 21,
2011).
Hu, J., Johnston, K.P., Williams III., R.O., 2004. Rapid dissolving
high potency danazol powders produced by spray freezing into
liquid process. Int. J. Pharm. 271, 145–154.
Leuner, C., Dressman, J., 2000. Improving drug solubility for oral
delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50, 47–
60.
Lipinski, C., 2002. Poor aqueous solubility-an industry wide problem
in drug delivery. Am. Pharm. Rev. 5, 82–85.
Margarit, M.V., Rodriguez, I.C., Cerezo, A., 1994. Physical charac-
teristics and dissolution kinetics of solid dispersions of ketoprofen
on polyethylene glycol 6000. Int. J. Pharm. 108, 101–107.
Moore, J.W., Flanner, H., 1996. Mathematical comparison of disso-
lution proﬁles. Pharm. Tech. 20, 64–74.
Roger, J.A., Anderson, A.J., 1982. Physical characteristic and disso-
lution proﬁles of ketoprofen-urea solid dispersion. Pharm. Act.
Helv. 57, 276–282.
Serajuddin, A.T.M., 1999. Solid dispersion of poorly water soluble
drugs: early promises, subsequent problems, and recent break-
throughs. J. Pharm. Sci. 88, 1058–1066.
Sheen, P.C., Khetarpal, V.K., Cariola, M.C., Rowlings, C.E., 1995.
Formulation studies of a poorly water-soluble drug in solid
dispersions to improve bioavailability. Int. J. Pharm. 118, 221–227.
Takayama, K., Nambu, N., Nagai, T., 1982. Factors affecting the
dissolution of ketoprofen from solid dispersions in various water
soluble polymers. Chem. Pharm. Bull. 3, 3013–3019.
Wyatt, D.A., 1999. Taking poorly water soluble compounds through
discovery. In: Recent Advances in the Formulations and Develop-
ment of Poorly Soluble Drugs. Bulletin Technique Gattefosse, pp.
31–39.
